tbuckley/cabot-search huggingface dataset:
Patient‐reported outcome measures for facial skin cancer: a systematic review and evaluation of the quality of their measurement properties
Authors: T.D. Dobbs, H. Samarendra, S. Hughes, H.A. Hutchings, I. Whitaker
Journal: British Journal of Dermatology (2018)

Background Skin cancer is the commonest malignancy worldwide, often occurring on the face. Both the condition and treatment can lead to scarring and facial disfigurement, affecting a patient's health-related quality of life (HRQoL), which can be measured using patient-reported outcome measures (PROMs). Objectives This systematic review identifies PROMs for facial skin cancer and appraises their methodological quality and psychometric properties using up-to-date methods. Methods MEDLINE, Embase, PsycINFO, Cochrane and CINAHL were searched systematically in accordance with PRISMA guidelines, identifying all PROMs designed for or validated in facial skin cancer. Methodological quality and evidence of psychometric properties were assessed using the COnsensus-based Standards for the Selection of Health Measurement INstruments (COSMIN) checklist and criteria proposed by Terwee and colleagues. A best-evidence synthesis and assessment of instrument focus on post-resection reconstruction was also performed. Results We included 24 studies on 11 PROMs. Methodological quality and psychometric evidence was variable, with the Patient Outcome of Surgery – Head/Neck (POS-H/N), Skin Cancer Index (SCI), Skin Cancer Quality of Life Impact Tool (SCQOLIT) and Essers and colleagues demonstrating the greatest level of validation. None scored well in their relevance to post-skin cancer reconstruction of the face. Conclusions This systematic review critically appraises PROMs for facial skin cancer using internationally accepted criteria. The identified PROMs demonstrate a variation in the quality of validation performed, with a need to improve this across all PROMs in the field. Only through improving the quality of available PROMs and their focus on the post-treatment aesthetic and functional outcome will we be able to truly appreciate the concerns of our patients and improve the management of facial skin cancer.
Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials
Authors: Shalender Bhasin, Susan S Ellenberg, Thomas W Storer, Shehzad Basaria, Marco Pahor, Alisa J Stephens-Shields, Jane A Cauley, Kristine E Ensrud, John T Farrar, David Cella, Alvin M Matsumoto, Glenn R Cunningham, Ronald S Swerdloff, Christina Wang, Cora E Lewis, Mark E Molitch, Elizabeth Barrett-Connor, Jill P Crandall, Xiaoling Hou, Peter Preston, Denise Cifelli, Peter J Snyder, Thomas M Gill
Journal: The Lancet Diabetes & Endocrinology (2018)
Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial
Authors: K.N. Moore, N. Colombo, G. Scambia, B.-G. Kim, A. Oaknin, M. Friedlander, A. Lisyanskaya, A. Floquet, A. Leary, G.S. Sonke, C. Gourley, S. Banerjee, A.M. Oza, A. González-Martín, C. Aghajanian, W. Bradley, E.S. Lowe, R. Bloomfield, P. DiSilvestro
Journal: Annals of Oncology (2018)
Dose finding and safety study of reovirus (Reo) with irinotecan/ fluorouracil/ leucovorin/ bevacizumab (FOLFIRI/B) in patients with KRAS mutant metastatic colorectal cancer (mCRC): Final results
Authors: S. Goel, A. Ocean, R. Parakrama, M.H. Ghalib, I. Chaudhary, U. Shah, M. Coffey, E. Kaledzi, R. Maitra
Journal: Annals of Oncology (2018)
Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)
Authors: J.R. Hecht, A. Naing, G.S. Falchook, M.R. Patel, R. Aljumaily, D.J. Wong, K.A. Autio, Z.A. Wainberg, M. Javle, J. Bendell, S. Pant, A. Hung, M. Oft, J. Leveque, K.P. Papadopoulos
Journal: Annals of Oncology (2018)
P2.01-33 Open-Label, Biomarker-Directed Platform Study in NSCLC Patients Who Progressed on an Anti-PD-(L)1 Containing Therapy (HUDSON)
Authors: P. Forde, J. Heymach, M. Thomas, K. Park, B. Besse, M. Awad, G. Goss, N. Rizvi, H. Ambrose, P. Jewsbury, B. Koetz, S. Lao-Sirieix, P. Mortimer, S. Patel, K. Sachsenmeier, W. Brugger
Journal: Journal of Thoracic Oncology (2018)
Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC)
Authors: M. Untch, C. Jackisch, A. Schneeweiss, S. Schmatloch, B. Aktas, C. Denkert, C. Schem, H. Wiebringhaus, S. Kümmel, K. Rhiem, M. Warm, P.A. Fasching, M. Just, C. Hanusch, J. Hackmann, J.-U. Blohmer, J. Furlanetto, V. Nekljudova, G. von Minckwitz, S. Loibl
Journal: Annals of Oncology (2018)
Antibacterial efficacy of handrubbing for 15 versus 30 seconds: EN 1500-based randomized experimental study with different loads of Staphylococcus aureus and Escherichia coli
Authors: D. Pires, H. Soule, F. Bellissimo-Rodrigues, M.E.A. de Kraker, D. Pittet
Journal: Clinical Microbiology and Infection (2018)

Compliance with the World Health Organization 'how to handrub' action is suboptimal. Simplifying the hand-hygiene action may improve practice. However, it is crucial to preserve antibacterial efficacy. We tested the non-inferiority of 15 versus 30 seconds handrubbing for Staphylococcus aureus and Escherichia coli contamination at different loads, using hand-size customized alcohol-based handrub (ABHR) volumes.In an EN1500-based study, 18 health-care workers (HCWs) with extensive experience in hand hygiene rubbed hands with a hand-size customized volume of isopropanol 60% v/v. They repeated the following sequence: hand contamination (E. coli or S. aureus; broth containing 108 or 106 CFU/mL); baseline fingertips sampling; handrubbing (15 or 30 seconds); re-sampling. The main outcome was log10 CFU corrected reduction factor (cRF) on HCWs' hands, applying a generalized linear mixed model with a random intercept for subject.The median cRF was 2.1 log10 (interquartile range 1.50-3.10). After fitting the model, cRF was significantly higher for S. aureus compared with E. coli but there was no significant effect for duration of handrubbing or contamination fluid concentration. Fifteen seconds of handrubbing was non-inferior to 30 (-0.06 log10, 95% CI -0.34 to 0.22; EN1500 0.60 log10 non-inferiority margin). This was confirmed in all pre-specified subgroups.Among experienced HCWs using a hand-size customized volume of ABHR, handrubbing for 15 seconds was non-inferior to 30 seconds in reducing bacterial load, irrespective of type of bacteria or contamination fluid concentration. This provides further support for a shorter, 15-seconds, hand-hygiene action.
Hypoxia-responsive lipid-poly-(hypoxic radiosensitized polyprodrug) nanoparticles for glioma chemo- and radiotherapy
Authors: Lei Hua, Zhen Wang, Liang Zhao, Honglin Mao, Guanghui Wang, Kairuo Zhang, Xuejiao Liu, Dongmei Wu, Yuanlin Zheng, Jun Lu, Rutong Yu, Hongmei Liu
Journal: Theranostics (2018)

Treatment of malignant glioma is a challenge facing cancer therapy. In addition to surgery, and chemotherapy, radiotherapy (RT) is one of the most effective modalities of glioma treatment. However, there are two crucial challenges for RT facing malignant glioma therapy: first, gliomas are known to be resistant to radiation due to their intratumoral hypoxia; second, radiosensitizers may exhibit a lack of target specificity, which may cause a lower concentration of radiosensitizers in tumors and toxic side effects in normal tissues. Thus, novel angiopep-2-lipid-poly-(metronidazoles)n (ALP-(MIs)n) hypoxic radiosensitizer-polyprodrug nanoparticles (NPs) were designed to enhance the radiosensitizing effect on gliomas. Methods: In this study, different degrees and biodegradabilites of hypoxic radiosensitizer MIs-based polyprodrug (P-(MIs)n) were synthesized as a hydrophobic core. P-(MIs)n were mixed with DSPE-PEG2000, angiopep-2-DSPE-PEG2000 and lecithin to self-assemble ALP-(MIs)n through a single-step nanoprecipitation method. The ALP-(MIs)n encapsulate doxorubicin (DOX) (ALP-(MIs)n/DOX) and provoke the release of DOX under hypoxic conditions for glioma chemo- and radiotherapy. In vivo glioma targeting was tested in an orthotopic glioma using live animal fluorescence/bioluminescence imaging. The effect on sensitization to RT of ALP-(MIs)n and the combination of chemotherapy and RT of ALP-(MIs)n/DOX for glioma treatment were also investigated both in vitro and in vivo. Results: ALP-(MIs)n/DOX effectively accumulated in gliomas and could reach the hypoxic glioma site after systemic in vivo administration. These ALP-(MIs)n showed a significant radiosensitizing effect on gliomas and realized combination chemotherapy and RT for glioma treatment both in vitro and in vivo. Conclusions: In summary, we constructed a lipid-poly-(hypoxic radiosensitized polyprodrug) nanoparticles for enhancing the RT sensitivity of gliomas and achieving the combination of radiation and chemotherapy for gliomas.
P2.03-15 Integrin-Linked Kinase (ILK), Protein Tyrosine Phosphatase SHP2 and B lymphoma Mo-MLV Insertion Region 1 Homolog (Bmi-1) in EGFR-Mutant NSCLC
Authors: N. Karachaliou, I. Chaib, J. Bracht, M. Filipska, A. Drozdowskyj, A. Cardona, A. Vergnenegre, J.M. Sánchez-Torres, M. Provencio, F. De Marinis, E. Carcereny, N. Reguart, R. García Campelo, M. Santarpia, S. Viteri, T. Bivona, R. Rosell
Journal: Journal of Thoracic Oncology (2018)
A phase I study of IRISOX (irinotecan/S-1/oxaliplatin) in the second-line treatment for gemcitabine-refractory pancreatic cancer
Authors: E. Miyata, K. Okuwaki, H. Imaizumi, M. Kida, T. Iwai, H. Yamauchi, T. Kaneko, R. Hasegawa, K. Adachi, M. Tadehara, W. Koizumi
Journal: Annals of Oncology (2018)
P1.15-17 Risk Factors of Local Recurrence in EGFR-Mutant Stage III-pN2 Adenocarcinoma After Complete Resection: A Multi-Center Real-World Cohort Study
Authors: Q. Li, B. Qiu, W. Liang, J. Wang, W. Hu, S. Xu, S.H. Lin, J. López, N. Chen, T. Zhang, M. Guo, Y. Zhao, S. Liu, Q. Liu, J. Guo, L. Cai, S. Wang, X. Wang, L. Zhang, T. Rong, Z. Yu, J. Yun, G. Wu, L. Zhang, V. Fang, H. Long, Q. Pang, H. Liu
Journal: Journal of Thoracic Oncology (2018)
P1.12-05 Efficacy of Perioperative Chemotherapy for High-Grade Neuroendocrine Tumors
Authors: H. Ogawa, Y. Tanaka, Y. Kitamura, H. Tanaka, Y. Nishioka, S. Tane, W. Nishio, Y. Maniwa, M. Yoshimura
Journal: Journal of Thoracic Oncology (2018)
P2.03-11 PDGFRA Defines a Unique Molecular Subtypes of Chinese Non-Small Cell Lung Cancer Patients
Authors: C. Xu, W. Wang, Q. Zhang, W. Zhuang, Y. Zhu, Y. Chen, M. Fang, G. Chen, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
P2.01-39 Can Benefit or Futility in Treating Advanced Nsclc Be Determined Early Using the LCSS 3-Item Global Index (3-IGI) PRO?
Authors: R. Gralla, P. Hollen, R. Hall, R. Gentzler, H. Cheng, B. Halmos, J. Crawford, J. Cerise, M. Lesser
Journal: Journal of Thoracic Oncology (2018)
Multicenter feasibility study of physician orders for life-sustaining treatment (POLST) for terminal cancer patients
Authors: H.J. An, H.J. Jeon, J. Cheon, S.H. Chun, H.A. Jung, H.K. Ahn, K.H. Lee, M.-H. Kim, J.H. Kim, S. Kim, S.-J. Koh
Journal: Annals of Oncology (2018)
Phase I study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1
Authors: C.-C. Lin, T. Doi, K. Muro, M.-M. Hou, T. Esaki, H. Hara, H.-C. Chung, M. Osada, C. Helwig, S. Kondo
Journal: Annals of Oncology (2018)
PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials
Authors: T.K. Choueiri, A. Flaifel, W. Xie, D. Braun, M. Ficial, R. Jennings, A. Nassar, B. Escudier, D.J. George, R.J. Motzer, M.J. Morris, T. Powles, E. Wang, Y. Huang, G. Freeman, S. Signoretti
Journal: Annals of Oncology (2018)
Carbohydrate antigen 19-9 and apolipoprotein A2 isoform as early detection biomarkers for pancreatic cancer: A prospective evaluation by the EPIC study
Authors: K. Honda, V. Katzke, A. Hüsing, S. Okaya, H. Shoji, K. Onidani, F. Canzian, R. Kaaks
Journal: Annals of Oncology (2018)
Randomized trial of androgen deprivation therapy (ADT) + enzalutamide (Arm A) versus ADT + bicalutamide (Arm B) in metastatic hormone sensitive prostate cancer (mHSPC)
Authors: U.N. Vaishampayan, L. Heilbrun, P. Monk, G. Sonpavde, S. Tejwani, E.I. Heath, J. Fontana, S. Chinni
Journal: Annals of Oncology (2018)
Assessment of PD-1/PD-L1 colocalization in hepatocellular carcinoma (HCC) using bright-field double labeling and quantitative digital image analysis
Authors: T. Mrowiec, F. Wilm, E. Frick-Krieger, M. Silva, L. Terracciano, I. Dussault, C. Ihling
Journal: Annals of Oncology (2018)
Improving the Diagnostic Performance of <sup>18</sup> F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography in Prosthetic Heart Valve Endocarditis
Authors: Laurens E. Swart, Anna Gomes, Asbjørn M. Scholtens, Bhanu Sinha, Wilco Tanis, Marnix G.E.H. Lam, Maureen J. van der Vlugt, Sebastian A.F. Streukens, Erik H.J.G. Aarntzen, Jan Bucerius, Sander van Assen, Chantal P. Bleeker-Rovers, Peter Paul van Geel, Gabriel P. Krestin, Joost P. van Melle, Jolien W. Roos-Hesselink, Riemer H.J.A. Slart, Andor W.J.M. Glaudemans, Ricardo P.J. Budde
Journal: Circulation (2018)

18F-Fluorodeoxyglucose (FDG) positron-emission tomography/computed tomography (PET/CT) was recently introduced as a new tool for the diagnosis of prosthetic heart valve endocarditis (PVE). Previous studies reporting a modest diagnostic accuracy may have been hampered by unstandardized image acquisition and assessment, and several confounders, as well. The aim of this study was to improve the diagnostic performance of FDG PET/CT in patients in whom PVE was suspected by identifying and excluding possible confounders, using both visual and standardized quantitative assessments.In this multicenter study, 160 patients with a prosthetic heart valve (median age, 62 years [43-73]; 68% male; 82 mechanical valves; 62 biological; 9 transcatheter aortic valve replacements; 7 other) who underwent FDG PET/CT for suspicion of PVE, and 77 patients with a PV (median age, 73 years [65-77]; 71% male; 26 mechanical valves; 45 biological; 6 transcatheter aortic valve replacements) who underwent FDG PET/CT for other indications (negative control group), were retrospectively included. Their scans were reassessed by 2 independent observers blinded to all clinical data, both visually and quantitatively on available European Association of Nuclear Medicine Research Ltd-standardized reconstructions. Confounders were identified by use of a logistic regression model and subsequently excluded.Visual assessment of FDG PET/CT had a sensitivity/specificity/positive predictive value/negative predictive value for PVE of 74%/91%/89%/78%, respectively. Low inflammatory activity (C-reactive protein <40 mg/L) at the time of imaging and use of surgical adhesives during prosthetic heart valve implantation were significant confounders, whereas recent valve implantation was not. After the exclusion of patients with significant confounders, diagnostic performance values of the visual assessment increased to 91%/95%/95%/91%. As a semiquantitative measure of FDG uptake, a European Association of Nuclear Medicine Research Ltd-standardized uptake value ratio of ≥2.0 was a 100% sensitive and 91% specific predictor of PVE.Both visual and quantitative assessments of FDG PET/CT have a high diagnostic accuracy in patients in whom PVE is suspected. FDG PET/CT should be implemented early in the diagnostic workup to prevent the negative confounding effects of low inflammatory activity (eg, attributable to prolonged antibiotic therapy). Recent valve implantation was not a significant predictor of false-positive interpretations, but surgical adhesives used during implantation were.
P2.16-28 Comparison of Outcomes of VATS Segmentectomy Versus Lobectomy for Non-Small Cell Lung Cancer Using a Propensity Score Matching Analysis
Authors: Y. Hwang, K. Hyun, S. Park, H.J. Lee, I.K. Park, Y. Kim, C.H. Kang
Journal: Journal of Thoracic Oncology (2018)
mRNA expression of ER, PR, HER2 and Ki67 are concordant to central ihc and predict clinical outcome: A validation study from the ABCSG-6 biomarker cohort
Authors: M. Filipits, M. Rudas, C. Singer, Z. Bago-Horvath, R. Greil, M. Balic, S.F. Lax, N. Wu, S. Zhao, J. Weidler, M. Bates, D. Hlauschek, M. Gnant, P. Dubsky
Journal: Annals of Oncology (2018)
Afatinib versus erlotinib as second-line treatment of patients (pts) with advanced lung squamous cell carcinoma (SCC): Final analysis of the global phase III LUX-Lung 8 (LL8) trial
Authors: G.D. Goss, M. Cobo, S. Lu, K. Syrigos, K.H. Lee, E. Göker, V. Georgoulias, W. Li, D. Isla, A. Morabito, Y.J. Min, A. Ardizzoni, A. Cseh, S. Bender, E. Felip
Journal: Annals of Oncology (2018)
P2.13-39 A Phase Ib Trial of the HSP90 Inhibitor AUY922 in Combination with Pemetrexed in Metastatic Non-Squamous, Non-Small Cell Lung Cancer Patients
Authors: Z. Noor, J.W. Goldman, W. Lawler, D. Melancon, B. Telivala, F. Braiteh, B. Dicarlo, K. Kennedy, D. Martinez, B. Adams, X. Wang, B. Jones, E. Garon
Journal: Journal of Thoracic Oncology (2018)
P1.03-32 Molecular Characteristics and Prognosis FBXW7 Mutations in Chinese Non-Small-Cell Lung Cancer Patients
Authors: C. Xu, W. Wang, Q. Zhang, W. Zhuang, Y. Zhu, Y. Chen, M. Fang, G. Chen, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
MA08.11 Early Safety Data of a Phase I/II Combining Nivolumab and Stereotactic Brain Radiosurgery for Treatment of Brain Metastases in Patients with NSCLC
Authors: R. Alameddine, P. Wong, L. Masucci, D. Roberge, C. Menard, B. Routy, M. Tehfe, N. Blais, M. Florescu
Journal: Journal of Thoracic Oncology (2018)
OA08.05 Quantifying Tumour Infiltrating Lymphocytes (TILs) in Malignant Pleural Mesothelioma (MPM) -Defining the Hot, the Warm and the Cold Tumours.
Authors: B. Thapa, M. Walkeiwicz, G. Rivalland, C. Murone, K. Asadi, S. Barnett, S. Knight, S. Hendry, P. Russell, T. John
Journal: Journal of Thoracic Oncology (2018)
The neutrophil-to-lymphocyte ratio (NLR) as a predictive marker of response to abiraterone acetate: A retrospective analysis of the COU302 study
Authors: T. Loubersac, S. Chakak, M. Nguile-Makao, V. Fradet, P. Toren
Journal: Annals of Oncology (2018)

Background: The neutrophil–lymphocyte ratio (NLR) is recognized as a prognostic marker in many cancers, including metastatic castration-resistant prostate cancer (mCRPC). In this study, we perform a retrospective analysis of the pivotal COU302 study of abiraterone acetate (AA) as first line therapy for men mCRPC. Methods: The COU302 study randomized men with minimally symptomatic mCRPC to 1000mg AA once daily plus 5mg prednisone (AA + P) twice daily or placebo plus 5mg prednisone (P) twice daily. We utilized Kaplan–Meier survival and cox proportional hazard analyses to assess the effect of baseline NLR on response to AA + P versus P. Adjustment co-variates were selected from a recently reported analysis of the PREVAIL study of enzalutamide in men with mCRPC. Based on this analysis, we selected a NLR cut-off value of 2.5. Outcomes assessed included the co-primary endpoints from the COU302 study overall survival (OS) , radiographic progression free-survival (RPFS) and PSA progression-free survival (PFS). Results: Among the 1088 patients in the COU302 study, baseline NLR values showed significant differences according to baseline albumin below median (3.16 vs 2.92, p = 0.011), but no other baseline covariates. Mean NLR significantly increased following treatment initiation and at the end of study compared to baseline. Among patients with a baseline NLR ≥2.5, there was similar OS in AA + P and P treatment arms (p = 0.26), which was confirmed on adjusted cox proportional hazards (AA +P HR 0.95, p = 0.65). AA + P showed a significant OS benefit versus P (p = 0.0011) in men with baseline NLR <2.5, with an adjusted HR of 0.723(p = 0.012). For RPFS, benefits for AA + P were seen in men with NLR <2.5 or ≥ 2.5, with the magnitude of benefit greater in men with NLR <2.5. In the AA + P arm, men with baseline NLR <2.5 had significantly better PSA PFS compared to baseline NLR ≥2.5 (p = 0.03); no significant differences were seen in men in the placebo arm. Conclusions: In the COU302 study, we observed that patients with a screening NLR<2.5 had a significant benefit to AA + P compared to P, whereas for patients with a screening NLR ≥2.5, this benefit was less evident. Increases in the NLR value from baseline could not be used to predict response to AA. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: V. Fradet: Speaker: Abbvie, Bayer, Ferring, Janssen, Sanofi; Consultant: Amgen, AstraZeneca, Astellas, Bayer, Ferring, Janssen, Sanofi; Adviser: Amgen, Astellas, Bayer, Ferring, Janssen, Sanofi; Research grant: Amgen, AstraZeneca, Astellas, Janssen, Sanofi; Clinical trial: AstraZeneca, Bayer, Janssen; Meeting sponsor: Bayer, Janssen, Lilly; Educational grant: Janssen. P. Toren: Scientific study or trial: Innocrin Pharma, Roche; Consultant, Advisor: Sanofi Canada, Ferring, Astellas, Abbvie. All other authors have declared no conflicts of interest.
Interim analysis of the non-interventional study QoLiTrap (AIO-LQ-0113) in patients with metastatic colorectal cancer (mCRC) treated with aflibercept (AFL) + FOLFIRI: Efficacy according to age group ≤65 and &gt;65 years
Authors: R.D. Hofheinz, H.-G. Derigs, G. Piringer, R. von Moos
Journal: Annals of Oncology (2018)
A pooled analysis of individual patient data (IPD) of concurrent chemoradiotherapy for limited-stage small cell lung cancer (LS-SCLC) in elderly compared to younger patients (pts) who participated in US National Cancer Institute cooperative group studies
Authors: T.E. Stinchcombe, W. Fan, S.E. Schild, E.E. Vokes, J. Bogart, Q.-T.X. Le, C.R. Thomas, M. Edelman, L. Horn, R. Komaki, H.J. Cohen, A.K. Ganti, H. Pang, X. Wang
Journal: Annals of Oncology (2018)
The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer
Authors: Qiqing Sun, Bo Zhang, Qiangsheng Hu, Yi Qin, Wenyan Xu, Wensheng Liu, Xianjun Yu, Jin Xu
Journal: Theranostics (2018)

Pancreatic ductal adenocarcinoma (PDAC) constitutes one of the most challenging lethal tumors and has a very poor prognosis.In addition to cancer cells, the tumor microenvironment created by a repertoire of resident and recruited cells and the extracellular matrix also contribute to the acquisition of hallmarks of cancer.Among these factors, cancer-associated fibroblasts (CAFs) are critical components of the tumor microenvironment.CAFs originate from the activation of resident fibroblasts and pancreatic stellate cells, the differentiation of bone marrow-derived mesenchymal stem cells and epithelial-to-mesenchymal transition.CAFs acquire an activated phenotype via various cytokines and promote tumor proliferation and growth, accelerate invasion and metastasis, induce angiogenesis, promote inflammation and immune destruction, regulate tumor metabolism, and induce chemoresistance; these factors contribute to the acquisition of major hallmarks of PDAC.Therefore, an improved understanding of the impact of CAFs on the major hallmarks of PDAC will highlight the diagnostic and therapeutic values of these targeted cells.
P1.09-26 A Case Report of Discordant Markers of Lung Cancer Tumor Cells: An Unusual Immunophenotype of Uncertain Significance
Authors: L. Giscombe, M. Keating, M. Dominguez, P. Changizzadeh, E. Jabbour, B. Aswad, R. Elbizri, B. Rathore
Journal: Journal of Thoracic Oncology (2018)
The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey
Authors: S. Kilickap, ÖF. Ölmez, I. Cicin, U. Demirci, O. Alan, D. Cabuk, T. Şakalar, A.M. Tatlı, F. Başol Buğdaycı, Y. Eralp, M. Uysal, A. Demirkazık, B. Bilgin, B. Yıldız, M. Karaağaç, K. Okutur, A. Sakin
Journal: Annals of Oncology (2018)